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ABSTRACT 
Oral delivery of pharmaceuticals requires that they retain their physical and chemical attributes 
during transit within the gastrointestinal (GI) tract, for the manifestation of desired therapeutic 
profiles. Solid lipid nanoparticles (SLNs) are used as carriers to improve the absorption of 
hydrophobic drugs. In this study, we examine the stability of amphotericin B (AmB) and 5 
paracetamol (PAR) SLNs in simulated GI fluids during gastric emptying. On contact with the 
simulated fluids, the particles increased in size due to ingress of the dissolution media into the 
particles. Simulated gastric emptying revealed that the formulations had mean sizes < 350 nm 
and neutral surface charges, both of which are optimal for intestinal absorption of SLNs. There 
was ingress of the fluids into the SLNs, followed by diffusion of the dissolved drug, whose rate 10 
depended on the solubility of the loaded-drug in the particular medium. Time-of-flight secondary 
ion mass spectrometry analyses indicated that drug loading followed the core-shell model and 
that the AmB SLNs have a more drug-enriched core than the PAR SLNs do. The AmB SLNs are 
therefore a very suitable carrier of AmB for oral delivery. The stability of the SLNs in the 
simulated GI media indicates their suitability for oral delivery. 15 
Keywords: Solid lipid nanoparticle, stability, gastrointestinal tract, gastric emptying, 
amphotericin B, paracetamol 
Chemical compounds studied in this article 

Amphotericin B (PubChem CID: 5386092); Paracetamol (PubChem CID: 1983); Sodium 
cholate (PubChem CID: 23668194) 20 
                                                          
AmB, amphotericin B; DLS, dynamic light scattering; GI, gastrointestinal; NTA, nanoparticle 
tracking analysis; PAR, paracetamol; PDI, polydispersity index; SGF, simulated gastric fluid; 
SIF, simulated intestinal fluid; SLN, solid lipid nanoparticle; ToF-SIMS, time-of-flight 
secondary ion mass spectrometry; ZP, zeta potential. 
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1. Introduction 
Ascertaining the stability of formulations in biological media can provide critical 
information for optimising such preparations, particularly for submicron formulations. Stability 
studies conducted in appropriate simulated GI media may give information on the fate of 
formulations after their oral administration. The stability of nanoparticulate formulations may be 25 
ascertained with reference to their chemical or pharmaceutical/storage stabilities (Muthu and 
Feng, 2009).  
After oral administration, a dosage form or drug must initially overcome the physical and 
chemical hydrodynamics within the GI tract and traverse the intestinal epithelium effectively in 
order to register significant bioavailability. Lipid-based delivery systems are susceptible to 30 
digestion/degradation by gastric and intestinal enzymes prior to their absorption. They can be 
absorbed by enterocytes as micelles, which improves the absorption of hydrophobic drugs 
(Müller et al., 1996; Pouton, 2000; Roger et al., 2009; Subramanian and Ghosal, 2004). In 
addition, solid lipid nanoparticles (SLNs) have a large surface area and are therefore prone to 
aggregation, which may reduce particle interaction with the intestinal mucosa (Jani et al., 1990).  35 
The slow drug release characteristics exhibited by SLN systems assure evasion of GI 
degradation of susceptible drugs; however, this may depend on the rate of degradation of the 
particles, which is also governed by the type of excipients used in formulating the SLNs (Damgé 
et al., 1990; Olbrich et al., 2002a, 2002b). A study by Zhang et al. revealed that using SLNs 
averted the gastric irritation caused by triptolide, which indicates that the delivery system retains 40 
its integrity in the stomach; however, the composition of the lipid matrix varies among 
formulations hence each SLN may respond differently (Zhang et al., 2013).  
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Amphotericin B (AmB) is a polyene antibiotic with broad-spectrum antifungal activity 
and an anti-leishmanial activity. It is used to treat systemic mycoses and it is particularly useful 
in immunocompromised patients as there is a high mortality rate in such patients due to invasive 45 
fungal infections (Wasan et al., 2009). AmB is currently administered intravenously due its poor 
aqueous solubility characteristics, which makes oral delivery challenging. In earlier studies, we 
have successfully formulated and exhaustively characterised an oral AmB-containing solid lipid 
nanoformulation with the aim of improving its oral bioavailability (Amekyeh et al., 2015; Tan et 
al., 2014; Tan et al., 2010). 50 
In the following, we investigate the stability of the AmB SLNs when challenged by 
simulated GI media. This was done in comparison with an identical SLN formulation containing 
paracetamol (PAR), which was used for studying the gastric empty pattern of the AmB SLNs. 
These SLNs have been characterised previously with regard to bioavailability and GI transit 
properties (Amekyeh et al., 2015). We aimed to specifically assess the changes in the surface 55 
chemistry and physical properties of the SLNs in simulated GI media and then extrapolate the 
data to the bioavailability study carried out earlier.  
 
2. Materials and methods 
2.1. Materials  60 
Paracetamol, simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) were 
purchased from Sigma-Aldrich (St. Louis, Missouri, USA). SGF and SIF were diluted with 
ultrapure water to obtain the media at pH 1.2 and pH 6.6 respectively. Beeswax was obtained 
from Acros Organics (New Jersey, USA), theobroma oil from JB Cocoa Company Limited 
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(Johor, Malaysia) and amphotericin B from Nacalai Tesque Inc. (Kyoto, Japan). Lecithin soy and 65 
sodium cholate were obtained from MP Biomedicals (Illkirch, France). Chloroform, ethyl acetate 
and methanol were purchased from Fisher Scientific (Loughborough, UK). All the reagents and 
solvents used were of analytical and HPLC grades respectively. Ultrapure water (18.2 MΩ·cm at 
25°C) was obtained using a Milli-Q system (Millipore Corp., Bedford, USA). 
 70 
2.2. Preparation of drug-free, AmB and PAR SLN formulations 
The drug-loaded SLNs were prepared according to the emulsification solvent diffusion 
technique, and characterised as described in our previous work (Amekyeh et al., 2015). Briefly, 
50 mg of drug, 120 mg of lecithin and 200 mg each of cocoa butter and beeswax were added to a 
40-mL mixture of chloroform and methanol (1:1). The solvent was evaporated off using a 75 
Rotavapor
®
 R-200/205 (Büchi, Switzerland) at 50°C. The resulting drug-lipid matrix was melted 
in 20 mL of ethyl acetate at 70°C and added to 40 mL of 2.5% w/v sodium cholate solution at 
70°C. The mixture homogenised (Ika-Turrax T 25
®
, IKA
®
, Staufen im Breisgau, Germany) at 10 
000 rpm for 6 min to prepare an emulsion. About 60 mL of water at 70°C was then added slowly 
to the mixture with continuous stirring for 20 min, after which the organic solvent was 80 
evaporated off. The drug-free formulation was similarly prepared without any drug.  
 
2.3. Stability of the SLNs in simulated GI fluids 
The SLN formulations were evaluated for their stability in SGF and SIF. An aliquot of 1 
mL of each formulation was placed in separate tubes containing SGF-only and SIF-only media, 85 
to produce a 1 in 250 dilution, which were then incubated for 2 hr. In a parallel study, the 
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formulations were incubated in SGF for 2 hr, followed by transfer into SIF and incubation for an 
additional 2 hr to mimic the gastric emptying process (SGF+SIF). All the SLN samples were 
diluted with the appropriate media to obtain a final dilution of 1 in 500 prior to analyses. The 
samples were then evaluated for size and surface charge changes using dynamic light scattering 90 
(DLS) and nanoparticle tracking analysis (NTA). Time-of-flight secondary ion mass 
spectrometry (ToF-SIMS) was used to qualitatively evaluate changes in the surface chemistries 
of the particles after their exposure to the media. 
 
2.4. DLS studies 95 
DLS studies on the SLNs were carried out using a Zetasizer Nano ZS
® 
(Malvern, UK) 
and the parameters measured were z-average diameter, zeta potential (ZP) and polydispersity 
index (PDI). Each analysis was carried out at 37°C and performed in triplicate. The data obtained 
are expressed as mean ± standard deviation (SD). 
 100 
2.5. NTA studies 
NTA measurements were performed using a NanoSight LM10 (NanoSight, Amesbury, 
United Kingdom) equipped with a sample chamber and a 640-nm laser. Using sterile syringes, 
samples were injected into the chamber to capacity. All measurements were done at 37°C. Each 
video was captured at 30 frames/sec for 1 min 30 sec and analysed using the NTA software 105 
version 3.1 Build 3.1.46. Triplicate measurements were performed for each sample and the data 
obtained have been expressed as mean ± SD.  
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2.6. ToF-SIMS analyses  
ToF-SIMS was carried out on the samples using an ION-TOF equipment (Münster, 
Germany) equipped with a liquid metal bismuth ion gun (LMIG). Prior to analyses, the SLNs 110 
were washed by centrifuging at 13 000 rpm for 60 min, after which the supernatants were 
discarded and deionised water added to the samples. The washing was done to remove ions from 
the simulated GI media off the particles, as these ions can affect signals in the spectra. The 
washing also helped to remove traces of unassociated drug during formulation. The precipitated 
particles were resuspended in water by shaking and the centrifugation process was repeated 115 
thrice. The washed SLNs were redispersed in deionised water and about 40 µL samples placed 
on labelled silicon wafers. The samples were then air-dried prior to analyses. The analyses were 
carried out using 25 keV Bi3
+
 primary ions over 200 μm × 200 μm areas. Data analyses were 
performed on the negative ion spectra for each sample using the ION-TOF software.  
 120 
3. Results and discussion 
3.1. DLS studies 
Z-average from a DLS measurement corresponds to the mean hydrodynamic diameter of 
the particles in a sample whilst PDI is a measure of the width of the particle size distribution. 
PDI values of 0.0-0.1 point to a narrow monodisperse distribution, 0.1-0.4 indicate a moderate 125 
polydisperse distribution system, whereas values greater than 0.4 indicate a broadly polydisperse 
system. Generally, particles in a sample with mean sizes above 500 nm and PDIs greater than 0.5 
are considered as “large or agglomerated”, which may not be truly representative of the sample. 
This is because few large particles present in a sample usually dominate the light scattering 
7 
 
signals in DLS analysis and give rise to large PDI values, which render the results unreliable. 130 
Nanoparticles with ZPs up to |10 mV| are considered “neutral” whereas those with ZPs greater 
than |30 mV| are considered “strongly charged” (Clogston and Patri, 2011). 
Fig. 1 shows the size distributions by intensity of drug-free and drug-loaded (AmB or 
PAR) SLNs whilst Fig. 2 illustrates the z-averages and PDIs of the SLNs, before and after 
exposure to the simulated fluids. Table 1 shows the ZP values of the SLN formulations in the 135 
various media.  
 
Table 1  
ZPs (mV) of drug-free and drug-loaded SLNs obtained from DLS. 
SLN 
formulation 
Fresh sample SGF-only SIF-only SGF+SIF  
Drug-free -67.6 ± 1.7 2.4 ± 0.3 -28.9 ± 0.6 -0.4 ± 0.1 
AmB -61.9 ± 1.0 1.1 ± 0.6 -31.2 ± 1.2 -3.0 ± 0.1 
PAR -71.9 ± 0.9 4.9 ± 1.1 -35.7 ± 0.5 3.4 ± 1.0 
 140 
The SGF contained approximately 2.0 g/L of NaCl and 2.917 g/L of HCl as specified in 
the United States and European Pharmacopoeias. SGF is less complex as compared with in vivo 
gastric fluid. However, the dominant features of stomach fluid are its acidity and ionic content, 
which are replicated with the SGF. 
8 
 
There was an approximately 3.8-fold increase in the z-average of the drug-free particles 145 
in SGF, which points to massive aggregation of the particles. The marked drop in the magnitude 
of ZP, as well as the change in surface charge from negative to positive (-67.6 ± 1.7 mV to 2.4 ± 
0.3 mV) can be attributed to the H
+ 
ions in SGF neutralising the negative charge density on the 
fresh SLNs. Furthermore, the reduction in ZP favours van der Waals type interparticle 
interactions, which result in particle aggregation.  150 
The SIF contained approximately 0.616 g/L of NaOH and 6.8 g/L of KH2PO4. In SIF-
only, there was a 1.8-fold increase in particle size and a 2.3-fold decrease in the ZP after 
exposure of the fresh particles to the medium. The PDI value indicates a relatively narrower size 
distribution width of the particles in SIF-only than in SGF-only and no aggregation of the SLNs 
in the former, which is due to retention of adequate surface charge (|28.9 mV|) above the 155 
threshold attendant for the agglomeration of colloidal particles (|15 mV|) (Riddick, 1968).  
The composition and volume of fluid along the GI tract, the motility of the GI tract, as 
well as the transit of dosage forms within it are highly variable. As a result, there is no perfect 
representative model for GI fluid. However, in the media exposure simulations described above, 
the SGF+SIF medium approximates the gastric emptying of contents into the small intestine, 160 
which is fairly consistent with that in the gut. Within the context of drug release and uptake of 
particles within the gut, surface chemistry and size changes of the particles are key determinants. 
Simulation of gastric emptying in respect of exposure to GI fluids was therefore a good measure 
of what might be happen in vivo. The z-average, PDI and ZP of the drug-free SLNs, as obtained 
in SGF+SIF were 517.0 ± 113.0 nm, 0.54 ± 0.22 and -0.4 ± 0.1 mV, respectively. Although a 165 
very low ZP magnitude is suggestive of particle agglomeration and subsequent precipitation, the 
PDI and mean particle size are intermediate between the values obtained in SGF-only and SIF-
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only. This probably suggests that the SLN aggregates in the SGF-only were held loosely as 
floccules, which then became deaggregated on exposure to SIF. A high ZP value is essential for 
the long-term storage stability of colloidal formulations. After oral administration however, only 170 
a sufficient ZP magnitude is necessary to maintain electrostatic repulsion among the particles 
prior to their absorption. As a result, a low ZP of nanoparticles after contact with GI fluids is not 
crucial in the present pursuit if their final size is optimal for absorption. 
A study by Shakweh et al. showed that uptake of neutral and negatively charged nano- 
and microparticles by Peyer’s patches in mice occurred to a greater extent as compared with that 175 
of positively charged particles (Shakweh et al., 2005). They observed a much larger number of 
particles with mean diameters of approximately 300 to 1000 nm in the patches than larger-sized 
particles. Again, particles with negative or close to neutral ZPs did not interact with the intestinal 
mucus gel layer due to electrostatic repulsion with the carboxylic (COO
-
) moiety of mucin, thus 
allowing such particles to reach the follicle-associated epithelium and subsequently the M cells, 180 
via endocytosis. Positively charged particles on the other hand were found to interact strongly 
with the mucus layer as the latter is negatively charged, resulting in an impeded uptake 
(Shakweh et al., 2005). 
The aforementioned results suggest that, in SGF+SIF, the drug-free particles retained 
their integrity as regards size and surface charge, which are critical features needed to augment 185 
absorption via endocytosis and subsequent lymphatic transport (Jani et al., 1989, 1994; Shakweh 
et al., 2005). The increase in size observed after exposure of the particles to the media may be a 
result of either aggregation or ingress of the dissolution media into the particles or both. The size 
distribution of the AmB SLNs (Fig. 1) in SGF-only was bimodal, and the two particle 
populations had mean sizes of 115.3 nm and 737.7 nm. As with the drug-free particles, the AmB 190 
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SLNs aggregated in SGF and after transfer from SGF into SIF, some deaggregation occurred. 
Prior to incubation, the AmB SLNs had z-average of 210.1 ± 1.4 nm, PDI of 0.22 ± 0.01 and ZP 
of -61.9 ±1.0 mV.  
There were no marked differences between the DLS data obtained for drug-free and 
AmB SLNs. Interestingly, both formulations showed an identical pattern of size change in the 195 
respective media, with the largest increase in size occurring in SGF-only, followed by SGF+SIF 
and then SIF-only. 
The increase in the sizes of the particles in SGF-only and SGF+SIF can be attributed to 
aggregation while the comparatively less marked size increase in SIF-only could be the result of 
influx of dissolution medium into the particles. The aggregation of the SLNs in SGF is likely to 200 
result in a reduced release of AmB from the particles due to a decrease in effective surface area. 
Consequently, aside from slow drug release from SLNs due to the hydrophobic nature of the 
lipid matrix, which retains most of the encapsulated drug within the matrix, particle aggregation 
in an acidic medium as observed above may further favour slow or no drug release in the 
stomach. This attribute is desirable as the small intestine, with its high expression of Peyer’s 205 
patches, is the probable site for uptake of the SLNs. Furthermore, the data obtained from our 
previous work in rats (Amekyeh et al., 2015) supports the assertion that AmB SLNs were taken 
up mostly from the small intestine.  
The PAR SLNs showed a bimodal distribution in SIF-only with mean sizes of 156.1 nm 
and 596.5 nm (Fig. 1). The size of the PAR SLNs was highest in SGF-only, followed by SIF-210 
only and then SGF+SIF. Generally, the increase in particle size after incubation in the media was 
lower for PAR SLNs as compared with the drug-free and AmB SLNs. 
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From previous studies, it appears that either a decrease or a size retention of various SLN 
formulations was observed in SGF-only (Jain et al., 2012; Laserra et al., 2015; Zhang et al., 
2013) while in SIF-only (Jain et al., 2012; Laserra et al., 2015; Roger et al., 2009; Yuan et al., 215 
2013), either an increase or a decrease in size was observed. It is likely that the composition of 
SLNs contribute to their propensity to aggregate as a function of GI media. In the present work, a 
size increase or aggregation of both drug-free and AmB-loaded SLNs was observed in the 
simulated GI fluids and this was manifested more in SGF-only.  
The hydrodynamic size obtained from DLS measurements can be affected by the salt 220 
concentration in a sample. This is due to the electrical double layer surrounding charged particles 
in an aqueous medium, which can be extended by the salts and result in an increase in size 
(Hackley and Clogston, 2011). In DLS, the intensity of scattered light is proportional to the 
square of particle diameter. Therefore, larger particles or clusters of smaller particles scatter light 
more strongly than smaller particles do (Balog et al., 2015). 225 
The marked increase in sizes of the SLNs observed in the present work could therefore be 
attributed to the few aggregated particles having approximate sizes of 5000 nm, which can be 
seen in each of the size distribution profiles for the fresh SLNs (Fig. 1). These large particles can 
perturb the light scattering signals, mask the presence of the smaller particles and lead to biased 
and possibly inaccurate size measurements.  230 
For samples containing significant differences in size populations such as the bimodal 
distributions of the AmB SLNs in SGF-only and the PAR SLNs in SIF-only, the calculated z-
averages do not convey very accurate size information. Although the DLS software has been 
designed to correct this aberration in multimodal distributions, the results may not reflect true 
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particle size distributions. As such, other particle sizing techniques can be used in addition to 235 
DLS in such instances (Lim et al., 2013). 
Overall, ZP was highest for the fresh SLN samples (Table 1). This is because the 
dispersion medium used to prepare the SLNs was deionised water. Hence, the negative surface 
charge on the fresh particles was solely due to the anionic surfactant (sodium cholate) used for 
formulating the SLNs. Incubating the SLNs in the simulated media resulted in a decrease in ZP, 240 
due the presence of electrolytes in the fluids. This is because ZP is dependent on the pH and 
conductivity of the suspending medium (Clogston and Patri, 2011). However, the decrease in ZP 
was more marked in SGF-containing media due to charge neutralisation by the H
+ 
ions present in 
SGF.  
In SGF+SIF, the drug-loaded SLNs had mean sizes ranging from 362.8 to 513.2 nm and 245 
neutral ZPs ranging from -10 to +10 mV. These properties favour the absorption of the SLNs via 
endocytosis by intestinal cells as well as via the Peyer’s patches through lymphatic transport 
(Clogston and Patri, 2011; Shakweh et al., 2005). We may conclude that the SLNs exhibit ideal 
physical properties necessary for absorption, following oral delivery and transit from the 
stomach to the small intestine. 250 
 
3.2. NTA studies 
In order to investigate the size variation of the SLNs in simulated GI fluids, free from the 
bias of DLS, the particle-by-particle approach for determining size using NTA was used. Fig. 3 
shows the mean particle size of the drug-free and drug-loaded SLNs, before and after their 255 
incubation in the various media. There was a general increase in size after incubating the 
13 
 
particles in the simulated media, except for the AmB SLNs in SGF+SIF and the PAR SLNs in all 
three media. The current results are suggestive of increase in particle size due to ingress of the 
media into the particles rather than of particle aggregation as indicative of the DLS data. The 
largest increase recorded for the drug-free particles was 94.1 nm and that was observed in 260 
SGF+SIF. 
For the AmB SLNs, there was an increase in size in SGF-only and SIF-only and a 
decrease in size in SGF+SIF. AmB is insoluble in water at pH 6-7 but soluble at pH 2 or 11 due 
to its amphoteric nature. It appears that SGF+SIF, having an approximate pH of 1.5, served as a 
better dissolution medium for AmB. In this regard, the diffusion of AmB from the particles 265 
resulted in a size decrease as opposed to the increase in size observed in the other media  
For the PAR SLNs, there was a decrease in size in all the three media and the largest 
decrease was observed in SGF+SIF. PAR is a hydrophilic drug and slightly soluble in water. 
PAR is also weakly acidic and forms a salt in strong acids (SGF) or bases however, the solubility 
of this salt depends on the ionic content of the dispersion medium. Since the dissolution of 270 
weakly acidic drugs is very minimal in strong acids, we observed identical size changes of the 
PAR SLNs in SGF-only and SIF-only (185.4 nm versus 182.7 nm, respectively), possibly 
indicating similar solubility characteristics of the drug at the two pHs respectively. In this regard, 
ingress of dissolution media into the particles would be followed by dissolution and diffusion out 
of the particles, resulting in the observed decrease in particle size. 275 
Comparing DLS and NTA, the latter is time-consuming and requires more operational 
skills but it clearly has benefits over DLS. NTA allows for sample visualisation, gives an 
approximate concentration of the particles in a sample and produces size data based on the 
Brownian motion of individual particles. The presence of few large particles in a sample has 
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little impact on the sizing accuracy of the NTA technique (Filipe et al., 2010). However, this is 280 
not the case in DLS, in which larger particles perturb and dominate the light scattering signals 
(Clogston and Patri, 2011). This could have been the reason for the observed differences in 
particle sizes from using the two techniques. In the present study, much larger particle sizes were 
obtained using DLS as compared with NTA although all the samples were similarly treated in 
the various media. Notwithstanding, the two techniques complement each other. 285 
In summary, contrasting patterns of size changes were observed for the drug-loaded 
SLNs in the various media. It appears that the size changes were dependent on the solubility of 
the incorporated drugs in the simulated fluids such that, ingress of the dissolution media into the 
SLNs caused some initial swelling of the particles. The dissolved drug was then free to diffuse 
out of the matrix of the particles, the rate of which depends on the aqueous solubility of the drug. 290 
Therefore, with PAR being the more hydrophilic drug in the present study, the PAR SLNs 
manifested a larger decrease in size due to the faster diffusion rate of the drug from the SLN 
matrices into the aqueous media. Particles with sizes below 10 µm are well taken up in the GI 
tract but uptake occurs more favourably when sizes are below 1000 nm (Jani et al., 1989; 
Kreuter, 1991; Shakweh et al., 2005). In addition, the mesh-pore spacing of the intestinal 295 
mucosal barrier is 50-1800 nm (Lai et al., 2010; Primard et al., 2010).  
The SLN formulations were found to be stable in the simulated GI fluids and are 
therefore deemed to be stable in vivo as well. The mean particle sizes and ZPs for all three 
formulations in the simulated media were also optimal for GI absorption meaning that the 
different particles would respond similarly with the GI mucus and epithelia. 300 
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3.3. ToF-SIMS analyses 
The negative and positive secondary ion spectra of the pure drugs, drug-free and drug-
loaded SLNs as well as the individual ingredients used for preparing the SLNs were subjected to 
ToF-SIMS analyses. However, only the negative ion spectra are presented as they provided data 305 
that were more meaningful as regards yields of the secondary ions of fragmented chemical 
components of the particles. In addition, the spectra for the individual non-drug components of 
the SLNs are not presented as these constituted the drug-free SLNs.  
The ions representing the diagnostic peaks used to identify AmB (C47H73NO17, 923.49 
g/mol) on the SLNs were [C20H27O2]
-
 at m/z 299.20, [C20H29O2]
-
 at m/z 301.22 and [C17H21NO4]
-
 310 
at m/z 303.23.  
 Comparing pure AmB with AmB SLNs, the peak intensities of the diagnostic ions (Fig. 
4(a)) indicated that the drug was present only in small quantities on the surface of the freshly 
prepared SLNs. As there was no drug loaded in the drug-free nanoparticles, the peaks 
corresponding to the diagnostic ions in the spectrum for the drug-free SLNs are due to the other 315 
ingredients used in preparing the nanoparticles. As a result, the peaks at m/z 299.20, 301.22 and 
303.23 in the spectrum for the AmB SLNs could be due to the excipients in the formulation, 
especially since the peak intensities are higher for the drug-free particles. These factors point to a 
drug-enriched SLN core and are a reflection of the high encapsulation efficiency of 91.2 ± 3.0% 
obtained for the AmB SLNs in our previous study (Amekyeh et al., 2015). 320 
 In Fig. 5(a), the relative intensities of AmB on the surfaces of the fresh SLNs and their 
after exposure to the media are compared. It can be observed that higher drug counts were 
detected on the particles after exposure of the SLNs to the GI media in the following order: 
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SGF+SIF > SIF-only > SGF-only. This trend is the reverse order of the particle size of the AmB 
SLNs in the respective media, as obtained from the NTA data. The higher intensities of the 325 
reference peaks for the media-exposed SLNs compared to the fresh sample points to the 
diffusion of AmB towards the surfaces of the SLNs. It is apparent that this diffusion to the 
surface is most effective in SGF+SIF and least so in SGF-only. Furthermore, this observation is 
in concert with the assertion that the diffusion of AmB from the SLN matrices is preceded by 
ingress of the media into the nanoparticles and dissolution of the payload, the speed of which 330 
may result in shrinkage of particles to various extents.  
 The diagnostic peak for PAR (C8H9NO2, 151.163 g/mol) is at m/z of 107.05, representing 
the [C7H7O]
-
 ion. The peak at m/z 107.05 (Fig. 4(b)) in the spectrum for the drug-free SLNs is 
attributable to the excipients used in the formulation. The intensity of the diagnostic peak was 
higher on the drug-loaded SLNs than on the drug-free particles, which indicates that the peak 335 
intensity observed on the SLNs is a combination of that for the drug itself as well as the 
excipients. This observation is the reverse of that detected in Fig. 4(a) for AmB. The results 
therefore indicate that there is a little amount of PAR on the surface of the fresh PAR SLNs, 
unlike the AmB SLNs, which had a negligible amount of AmB on the SLNs. 
 In Fig. 5(b), the spectra show a much intense PAR count on the fresh PAR nanoparticles 340 
in comparison to those incubated in the media. The PAR SLNs showed a relatively low 
encapsulation efficiency of 60.7 ± 0.26% (Amekyeh et al., 2015).  
 PAR is hydrolysed in acidic solutions (SGF) to produce 4-aminophenol and acetic acid; 
however, these products have different masses and would therefore not contribute to the signal 
intensity at m/z 107.05. This would manifest as a low PAR count on the particles in SGF-only as 345 
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compared with the fresh particles. Furthermore, PAR is very soluble at the pH of SIF, which 
favours drug release and dissolution in the medium resulting in an equally low drug count on the 
particles. As with the AmB SLNs, the highest drug intensity was detected on the PAR SLNs after 
their incubation in SGF+SIF, which indicates the latter as the best dissolution medium for both 
drugs. This means that there is a higher rate of drug diffusion out of the particles in SGF+SIF, 350 
which explains why the two SLNs had the smallest mean particle size in that medium (Fig. 3).  
The mean particle size (based on the NTA data) of the PAR SLNs after exposure to the 
media decreased in the order: SGF-only > SIF-only > SGF+SIF, and drug intensity on the SLNs 
was SIF-only < SGF-only < SGF+SIF. From Fig. 3, the mean sizes of the PAR nanoparticles in 
SGF-only and SIF-only are comparable (185.4 ± 53.9 nm and 182.7 ± 27.2 nm, respectively). 355 
Also, in Fig. 5(b), the intensity of the diagnostic peak is similar in the two media albeit slightly 
lesser in SIF-only, unequivocally signifying that the ultimate size of the particles is inversely 
related to the amount of drug released from the particles into the medium.  
 
4. Conclusions 360 
The data obtained indicate that after placing the SLNs in the simulated GI media, there 
was ingress of the fluids into the SLNs followed by diffusion of the dissolved drug. The rate of 
the diffusion however depended on the solubility of the loaded-drug in the particular medium. 
There was an increase in the size (NTA-based) of the drug-free SLNs in all the three media since 
the main mass transfer was the diffusion of the media into the SLNs and no drug diffusion out of 365 
the particles. The study showed NTA to be a more suitable technique than DLS for analysing the 
stability of the SLNs in the various media. The data obtained indicate that the SLNs after oral 
18 
 
ingestion may aggregate in the stomach. However, on reaching the small intestine, both the size 
and surface charge of the particles would be optimal for absorption. The mass spectra obtained 
from the ToF-SIMS analyses indicated that drug loading into the SLNs possibly followed the 370 
core-shell model and that the AmB SLNs may have a more drug-enriched core than the PAR 
SLNs do. The AmB SLNs are therefore a very suitable carrier of AmB for oral delivery. 
Furthermore, the stability of the SLN formulations in the simulated GI media indicated their 
suitability for oral delivery. 
 375 
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FIGURES 
 
Figure 1 Size distribution by intensity of drug-free and drug-loaded SLNs, before and 
after their exposure to simulated GI fluids. The analyses were conducted using 
DLS. Triplicate measurements were performed for each sample. 
 
 
Figure 2 Z-averages and PDIs of drug-free and drug-loaded SLNs, before and after 
their exposure to simulated GI fluids. The analyses were conducted using 
DLS. Triplicate measurements were performed for each sample. Data have 
been presented as mean ± standard deviation. 
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Figure 3 Mean particle diameter of drug-free and drug-loaded SLNs, before and after 
their exposure to simulated GI fluids. Measurements were done using NTA. 
Triplicate measurements were performed for each sample. Data have been 
presented as mean ± standard deviation. 
 
 
Figure 4 Negative ion ToF-SIMS spectra showing pure drugs [(a) AmB or (b) PAR], 
drug-free SLNs and the respective drug-loaded SLNs. [* = diagnostic peaks].  
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Figure 5 Negative ion ToF-SIMS spectra showing the drugs [(a) AmB or (b) PAR] on 
the surface of the respective fresh SLNs and after their incubation in simulated 
GI fluids. The asterisks represent the diagnostic peaks. 
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